GCTK

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.

Wall Street analysts forecast GCTK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GCTK is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

GlucoTrack Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

GlucoTrack Inc. EPS for the last quarter amounts to -4.64 USD, decreased -99.57 % YoY.

GlucoTrack Inc (GCTK) has 11 emplpoyees as of January 10 2026.

Today GCTK has the market capitalization of 3.42M USD.